Bristol-Myers Squibb (BMY) Announces Strong Data from Yervoy Phase 3 vs. Placebo in Melanoma Patients
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced superior efficacy with Yervoy 10 mg/kg versus placebo on all survival endpoints in the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
